2Shimodaira H, Takahashi K, Kano K, et al. Enhancement ofanticoagul by warfarin-benzbromarone interaction[J]. J Clin Pharmacol 1996, 36(2): 168-174.
3Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone[J]. Clin Phamacol Ther, 1999, 66(6): 569-581.
1Camm A J, Kirehhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC). Eur Heart J, 2010, 31 (19) : 2369-2429.
2Pascual-Figal DA, Hurtado-Martlnez JA, Redondo B, et al. Hypemricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail, 2007,9(5) : 518- 524.
3Shimodaira H, Takahashi K, Kano K, et al. Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J Clin Pharmacol, 1996, 36(2) : 168-174.
5Uchida S, Shimada K, Misaka S, et al. Benzbromarone phar- macokinetics and pharmacodynamics in different cytochrome P450 2C9 Genotypes. Drug Metab Pharmacokinet, 2010,25(6) : 605- 610.
6Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther, 1999, 66(6) : 569-581.
